Skip to main navigation
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
  • Careers
  • Contact Us
  • Policies
Active Clinical Trials
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Pancreatic Cancer & Advanced Solid Tumors LSTA1
    • Solid Tumors Tumor-Penetrating Nanocomplex (TPN) Platform™
    • Coronary Microvascular Dysfunction (CMD): XOWNA®
    • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) LSTA201
    • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CendR Platform™ Technology
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management
      • Board of Directors
    • Historical Information
      • Historical Press Releases
      • Historical SEC Filings
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Policies & Disclosures
  • Patients & Families
    • Overview
    • Metastatic Pancreatic Cancer Symptoms & Treatment
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
Investors & News / Financials & Filings / Investors & News / SEC Filings / 4 /

SEC Filing Details

Document Details

Form
4
Filing Date
Jan 11, 2023
Document Date
Jan 9, 2023
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Lisata Therapeutics, Inc.
Issuer
LISATA THERAPEUTICS, INC.
Filer
SLACK DAVID W.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Print Page
  • RSS Feeds
  • Email Alerts
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
Active Clinical Trials
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Pancreatic Cancer & Advanced Solid Tumors LSTA1
    • Solid Tumors Tumor-Penetrating Nanocomplex (TPN) Platform™
    • Coronary Microvascular Dysfunction (CMD): XOWNA®
    • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) LSTA201
    • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CendR Platform™ Technology
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Historical Information
    • Investor Resources
  • Patients & Families
    • Overview
    • Metastatic Pancreatic Cancer Symptoms & Treatment
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2023 Lisata Therapeutics, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100